TWI917367B - 經同位素標記之曲匹地（ｔｒａｐｉｄｉｌ）衍生物及其醫藥組合物與用途 - Google Patents

經同位素標記之曲匹地（ｔｒａｐｉｄｉｌ）衍生物及其醫藥組合物與用途

Info

Publication number
TWI917367B
TWI917367B TW110110928A TW110110928A TWI917367B TW I917367 B TWI917367 B TW I917367B TW 110110928 A TW110110928 A TW 110110928A TW 110110928 A TW110110928 A TW 110110928A TW I917367 B TWI917367 B TW I917367B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
eutectic
solvent
Prior art date
Application number
TW110110928A
Other languages
English (en)
Chinese (zh)
Other versions
TW202202502A (zh
Inventor
亞拉什 波德巴爾
寛子 正宗
沃倫 Ｓ 韋德
Original Assignee
美商斯諾皮亞生物科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商斯諾皮亞生物科學公司 filed Critical 美商斯諾皮亞生物科學公司
Publication of TW202202502A publication Critical patent/TW202202502A/zh
Application granted granted Critical
Publication of TWI917367B publication Critical patent/TWI917367B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
TW110110928A 2020-03-26 2021-03-25 經同位素標記之曲匹地（ｔｒａｐｉｄｉｌ）衍生物及其醫藥組合物與用途 TWI917367B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063000347P 2020-03-26 2020-03-26
US63/000,347 2020-03-26
US202063063846P 2020-08-10 2020-08-10
US63/063,846 2020-08-10

Publications (2)

Publication Number Publication Date
TW202202502A TW202202502A (zh) 2022-01-16
TWI917367B true TWI917367B (zh) 2026-03-11

Family

ID=77892379

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110110928A TWI917367B (zh) 2020-03-26 2021-03-25 經同位素標記之曲匹地（ｔｒａｐｉｄｉｌ）衍生物及其醫藥組合物與用途
TW114111322A TWI918457B (zh) 2020-03-26 2021-03-25 經同位素標記之曲匹地(trapidil)衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114111322A TWI918457B (zh) 2020-03-26 2021-03-25 經同位素標記之曲匹地(trapidil)衍生物

Country Status (11)

Country Link
US (1) US12508267B2 (cg-RX-API-DMAC10.html)
EP (1) EP4125853A4 (cg-RX-API-DMAC10.html)
JP (2) JP7730336B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230013023A (cg-RX-API-DMAC10.html)
CN (3) CN116496279B (cg-RX-API-DMAC10.html)
AU (1) AU2021244241A1 (cg-RX-API-DMAC10.html)
CA (1) CA3177066A1 (cg-RX-API-DMAC10.html)
IL (1) IL296788A (cg-RX-API-DMAC10.html)
MX (1) MX428433B (cg-RX-API-DMAC10.html)
TW (2) TWI917367B (cg-RX-API-DMAC10.html)
WO (1) WO2021195425A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054674A1 (en) 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
IL296788A (en) 2020-03-26 2022-11-01 Sinopia Biosciences Inc Isotopically labeled trepidil histories

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180243307A1 (en) 2016-04-04 2018-08-30 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
WO2007061798A2 (en) 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
NZ580662A (en) * 2007-04-30 2012-01-12 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
CA2721797C (en) 2008-04-18 2018-02-27 Gary Zabow Magnetic microstructures for magnetic resonance imaging
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
WO2017059118A1 (en) 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
WO2017117240A1 (en) 2015-12-29 2017-07-06 JONES AND MALTERER TECHNOLOGY INNOVATIONS INCORPORATED, d/b/a JAMTek Multi-point synchronizable and scalable lighting control systems
CA3087925A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP4069239A4 (en) 2019-12-02 2023-11-29 Sinopia Biosciences, Inc. Treating cognitive disorders using trapidil
IL296788A (en) 2020-03-26 2022-11-01 Sinopia Biosciences Inc Isotopically labeled trepidil histories
WO2021262786A1 (en) 2020-06-24 2021-12-30 Yale University Pank modulators and methods using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180243307A1 (en) 2016-04-04 2018-08-30 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Allan B. Foster, "Deuterium isotope effects in studies of drug metabolism." Trends in Pharmacological Sciences, Volume 5, 1984, Pages 524-527.

Also Published As

Publication number Publication date
JP2023519289A (ja) 2023-05-10
JP7730336B2 (ja) 2025-08-27
TW202202502A (zh) 2022-01-16
AU2021244241A1 (en) 2022-11-24
CN116496279A (zh) 2023-07-28
MX2022011879A (es) 2023-01-11
US12508267B2 (en) 2025-12-30
TW202547838A (zh) 2025-12-16
EP4125853A1 (en) 2023-02-08
US20230102580A1 (en) 2023-03-30
JP2025183224A (ja) 2025-12-16
IL296788A (en) 2022-11-01
KR20230013023A (ko) 2023-01-26
EP4125853A4 (en) 2024-07-03
WO2021195425A1 (en) 2021-09-30
CA3177066A1 (en) 2021-09-30
TWI918457B (zh) 2026-03-11
CN115916180A (zh) 2023-04-04
MX428433B (es) 2025-11-13
CN116496279B (zh) 2025-12-12
CN121550230A (zh) 2026-02-24

Similar Documents

Publication Publication Date Title
US11643390B2 (en) Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses
CN112479996B (zh) 吡啶氮氧化合物及其制备方法和用途
CA3213029A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
JP2025183224A (ja) 同位体標識トラピジル誘導体
TW202228716A (zh) 賽洛西賓(psilocybin)之氘化衍生物及其用途
EP3630115A1 (en) Compositions and methods for preparing and using mitochondrial uncouplers
CA2905573C (en) A crystalline form of an anxiolytic compound
JPS62120317A (ja) 痴呆症状改善・治療剤
EP4606798A1 (en) Benzoisothiazole compound, and pharmaceutical composition and use thereof
US6187807B1 (en) Methods of use and compositions of (S) (-)-amisulpride
EP4592287A1 (en) 2h-benzotriazole derivative, preparation method therefor, and pharmaceutical composition containing same
EP4520752A1 (en) Carebastine salt and use thereof
WO2023070120A1 (en) Ketoamides for treating malignancy
JPH0269417A (ja) 精神分裂病治療用組成物
PT95735B (pt) Processo para a preparacao de morfolinois e de composicoes farmaceuticas que os contem
HK40090744A (en) Isotopically-labelled trapidil derivatives
JP2010511055A (ja) アルコール乱用、嗜癖および依存の処置方法
US12180137B1 (en) Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof
JP7354245B2 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
CN109553607B (zh) 嘧啶甲酰胺衍生物及其制备方法、组合物、制剂和用途